558 related articles for article (PubMed ID: 7691188)
1. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
2. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
3. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
[No Abstract] [Full Text] [Related]
4. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
5. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
6. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
Blaese RM
Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
[TBL] [Abstract][Full Text] [Related]
10. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
Ramsey WJ; Mullen CA; Blaese RM
Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
[TBL] [Abstract][Full Text] [Related]
11. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
12. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow gene therapy for adenosine deaminase deficiency.
Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte gene therapy.
Culver KW; Anderson WF; Blaese RM
Hum Gene Ther; 1991; 2(2):107-9. PubMed ID: 1911929
[TBL] [Abstract][Full Text] [Related]
15. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.
Onodera M; Ariga T; Kawamura N; Kobayashi I; Ohtsu M; Yamada M; Tame A; Furuta H; Okano M; Matsumoto S; Kotani H; McGarrity GJ; Blaese RM; Sakiyama Y
Blood; 1998 Jan; 91(1):30-6. PubMed ID: 9414266
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells.
Cournoyer D; Scarpa M; Mitani K; Moore KA; Markowitz D; Bank A; Belmont JW; Caskey CT
Hum Gene Ther; 1991; 2(3):203-13. PubMed ID: 1751590
[TBL] [Abstract][Full Text] [Related]
17. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.
Ficara F; Superchi DB; Hernández RJ; Mocchetti C; Carballido-Perrig N; Andolfi G; Deola S; Colombo A; Bordignon C; Carballido JM; Roncarolo MG; Aiuti A
Mol Ther; 2004 Dec; 10(6):1096-108. PubMed ID: 15564141
[TBL] [Abstract][Full Text] [Related]
18. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
[TBL] [Abstract][Full Text] [Related]
20. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Cassani B; Montini E; Maruggi G; Ambrosi A; Mirolo M; Selleri S; Biral E; Frugnoli I; Hernandez-Trujillo V; Di Serio C; Roncarolo MG; Naldini L; Mavilio F; Aiuti A
Blood; 2009 Oct; 114(17):3546-56. PubMed ID: 19652199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
